Oncology for the Inquisitive Mind

Di: Michael Fernando and Josh Hurwitz
  • Riassunto

  • Cancer is a fascinating but rapidly evolving discipline - it's a full-time job just keeping up to date. In this podcast, Dr Michael Fernando and Dr Joshua Hurwitz explore the latest trials, research, and practice-changing updates, as well as regular interviews with renowned oncology specialists. Ideal for those starting their training journey, established specialists and anyone interested in medical science, oncological practice, or terrible jokes. Preferably all three.

    Hosted on Acast. See acast.com/privacy for more information.

    Michael Fernando and Josh Hurwitz
    Mostra di più Mostra meno
  • 141. Back to Basics - Endocrine Therapy and Breast Cancer
    Dec 21 2024

    Before immunotherapy, targeted chemotherapy (ADCs) and precision oncology, there was endocrine therapy, the forefather (or mother) of effective treatment to reduce cancer recurrence as well as delay disease progression. This episode dives into a past with fantastic hazard ratios, reduced risk of death, and phenomenal improvement in adjuvant space. How long should one take endocrine therapy? We cover all the facts you need to know as a clinician or if you are curious from a patient/learning perspective.


    Studies discussed in the episode:

    EBCTCG Group - 2011 + 2015

    ATLAS trial

    BIG 198

    Patient-level meta-analysis of the randomised trials


    For more episodes, resources and blog posts, visit www.inquisitiveonc.com

    Please find us on Twitter @InquisitiveOnc!

    If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com


    Art courtesy of Taryn Silver

    Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/


    Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.


    Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.


    Hosted on Acast. See acast.com/privacy for more information.

    Mostra di più Mostra meno
    24 min
  • 140. Back to Basics - Adjuvant HER2 Breast Cancer (Part 2)
    Dec 14 2024

    HER2 Breast Cancer is complicated, and this week, we explore those with residual disease post neoadjuvant therapy (KATHERINE) and the idea of de-escalation in a subpopulation of HER2-positive breast cancer patients (PERSEPHONE). The advent of a new class of drugs leads to excitement, unanswered questions and boundless opportunities. With ADC (antibody-drug conjugates) making their mark on traditional chemotherapy, the landscape of everything we treat is slowly changing.


    Studies discussed in the episode:

    KATHERINE

    PERSEPHONE


    For more episodes, resources and blog posts, visit www.inquisitiveonc.com

    Please find us on Twitter @InquisitiveOnc!

    If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com


    Art courtesy of Taryn Silver

    Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/


    Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.


    Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.


    Hosted on Acast. See acast.com/privacy for more information.

    Mostra di più Mostra meno
    19 min
  • 139. Back to Basics - Early HER2 Breast Cancer
    Dec 8 2024

    Human epidermal growth factor receptor 2 (HER2) is overexpressed in multiple cancers, including breast, gastric, colorectal, and epithelial ovarian cancers. However, this receptor's complexity doesn't stop there. It has multiple subdomains and various responses to drugs, and the complete picture is yet to be understood.


    This week, we explore the original wonder drug (Trastuzumab) in the early breast cancer space and its compatriot, Pertuzumab. Josh highlights the association between pathological complete responses and event-free survival/overall survival, while Michael looks at Neosphere and picks apart the data to help understand where this drug is most beneficial.



    Studies discussed in the episode:

    NEOSPHERE

    GEPARQUINTO

    NOAH TRIAL


    For more episodes, resources and blog posts, visit www.inquisitiveonc.com

    Please find us on Twitter @InquisitiveOnc!

    If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com


    Art courtesy of Taryn Silver

    Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/


    Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.


    Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.


    Hosted on Acast. See acast.com/privacy for more information.

    Mostra di più Mostra meno
    25 min

Cosa pensano gli ascoltatori di Oncology for the Inquisitive Mind

Valutazione media degli utenti. Nota: solo i clienti che hanno ascoltato il titolo possono lasciare una recensione

Recensioni - seleziona qui sotto per cambiare la provenienza delle recensioni.